Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value
TheFly reported on June 18 that Baird increased its price target on NRIX to $33 from $26 while maintaining an Outperform rating on the shares.
Nurix Therapeutics Inc. (NRIX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Vestal Point Capital Ryan Wilder | 8,050,000 | $195,293,000 | +24% | 4.56% |
| 2. | Deep Track Capital David Kroin | 7,736,455 | $187,686,398 | +22% | 2.73% |
| 3. | Rubric Capital Management David Rosen | 7,227,778 | $175,345,894 | +193% | 1.61% |
| 4. | Baker Bros. Advisors Julian Baker And Felix Baker | 4,658,556 | $113,016,569 | 0.57% | |
| 5. | Perceptive Advisors Joseph Edelman | 4,320,422 | $104,813,438 | +17% | 1.57% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.00 | 4,356 | $108,900.00 | 117,227 | 2026-08-05 | Filing | |
| $24.64 | 2,611 | $64,338.96 | 117,227 | 2026-08-04 | Filing | |
| $23.87 | 1,500 | $35,802.60 | 119,838 | 2026-08-04 | Filing | |
| $24.65 | 2,967 | $73,128.84 | 40,166 | 2026-08-04 | Filing | |
| $23.89 | 1,794 | $42,860.63 | 43,133 | 2026-08-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,770,349 | $212,768,666 | 0% | |
| 2. | 5,485,215 | $133,071,325 | 0.01% | |
| 3. | 4,762,484 | $115,537,879 | 0.01% | |
| 4. | 4,677,244 | $113,469,939 | 0% | |
| 5. | 4,495,529 | $109,061,534 | 0% |
News See All
10 Best Biotech Stocks to Buy According to Analysts
Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, rising merger activity, and renewed investor confidence.
9 Stocks Winning by Double Digits
Nine stocks clocked strong double-digit gains on Thursday, bucking a lackluster performance in the broader market, thanks to stellar earnings performance and acquisition news that sparked buying appetite...
8 Best Genomics Stocks to Buy According to Analysts
On June 8, 2026, Google DeepMind, Google.org, and the Wellcome Sanger Institute announced a five-year artificial intelligence collaboration for genomics.
Nurix Therapeutics Stock (NRIX) Soars 40% After $2.3B Blood Cancer Deal with Roche
Shares in biopharmaceutical company Nurix Therapeutics ($NRIX) soared nearly 40% in pre-market trading after sealing a $2.3 billion blood cancer de...
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
Joseph Edelman, the billionaire chief of New York-based Perceptive Advisors, specializes in the biotechnology and life sciences sectors.
Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best low priced biotech stocks to invest in. Wells Fargo cut the price target on Nurix Therapeutics, Inc.
8 Best Low Priced Biotech Stocks to Invest In
On April 16, Fundstrat’s Tom Lee appeared on CNBC's 'Closing Bell' to talk about what to expect from equity markets going forward.
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory
We came across a bullish thesis on Nurix Therapeutics, Inc. on Clinical Catalysts’s Substack. In this article, we will summarize the bulls’ thesis on NRIX.
Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts
TheFly reported on January 29 that Stifel raised the price target on NRIX to $35 from $33 and maintained a Buy rating.
Hedge Fund Resource Center